CSIMarket
 
Medpace Holdings Inc   (NASDAQ: MEDP)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $295.7700 $-10.85 -3.539%
Day's High: $303.41 Week Perf: -0.22 %
Day's Low: $ 292.53 30 Day Perf: 4.78 %
Volume (M): 371 52 Wk High: $ 459.77
Volume (M$): $ 109,731 52 Wk Avg: $349.69
Open: $302.22 52 Wk Low: $250.05



 Market Capitalization (Millions $) 9,227
 Shares Outstanding (Millions) 31
 Employees 5,900
 Revenues (TTM) (Millions $) 2,157
 Net Income (TTM) (Millions $) 416
 Cash Flow (TTM) (Millions $) 34
 Capital Exp. (TTM) (Millions $) 41

Medpace Holdings Inc
Medpace Holdings Inc. is a global contract research organization (CRO) that provides full-service clinical development solutions to its clients in the biopharmaceutical and medical device industries. Headquartered in Cincinnati, Ohio, the company was founded in 1992 by Dr. August Troendle, who still serves as its Chief Executive Officer.

Medpace offers a comprehensive range of clinical research services, including study design, protocol development, site identification and management, data management, biostatistics, regulatory affairs, clinical monitoring, medical writing, pharmacovigilance, and medical affairs. The company has specialized expertise in areas such as oncology, cardiology, neuroscience, infectious diseases, and rare diseases.

The company operates in over 45 countries and has a workforce of over 4,000 employees, including more than 1,200 medical personnel. Medpace has a proven track record of delivering high-quality clinical trials on time and within budget. As a result, it has established long-term partnerships with over 500 clients, ranging from small biotech startups to large pharmaceutical companies.

Medpace's quality management system is based on the principles of ICH Good Clinical Practice (GCP) and ISO 9001:2015. The company has been audited and inspected by regulatory authorities around the world, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Medpace went public in 2016, raising $172.5 million in its initial public offering (IPO) on the NASDAQ stock exchange. Since then, the company's stock has steadily grown, reflecting the company's strong financial performance and growth prospects.

In summary, Medpace Holdings Inc. is a leading global CRO that provides full-service clinical development solutions to its clients in the biopharmaceutical and medical device industries. With a proven track record, specialized expertise, and a commitment to quality, Medpace is well-positioned to meet the increasing demand for clinical trial services in the healthcare industry.


   Company Address: 5375 Medpace Way Cincinnati 45227 OH
   Company Phone Number: 579-9911   Stock Exchange / Ticker: NASDAQ MEDP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CRL   -2.82%    
IQV   -2.24%    
NOTV   -0.49%    
SHC   -3.14%    
TMO   -1.64%    
• View Complete Report
   



Business Update

Medpace Holdings, Inc. to Unveil Fiscal Year 2024 Financial Results Anticipation Grows for Q4 Insights on Febru...

Published Sat, Jan 4 2025 1:15 PM UTC

CINCINNATI Medpace Holdings, Inc. (Nasdaq: MEDP) has officially announced its plans to report the financial results for the fourth quarter and the entire fiscal year 2024 on February 10, 2025, after the market closes. This key announcement is poised to be a significant event for investors, analysts, and stakeholders, as it will provide detailed insights into the company?s ...

Business Update

Medpace Holdings Prepares for Year-End Financial Disclosure Amidst a Shifting Clinical Landscape

Published Fri, Jan 3 2025 11:08 AM UTC

As the biotech and clinical research industries remain in flux, Medpace Holdings, Inc. (Nasdaq: MEDP) is set to release its fourth quarter and fiscal year 2024 financial results on February 10, 2025. The Cincinnati-based company has announced that the results will be disclosed after market hours, followed by a conference call on February 11, 2025, at 9:00 a.m. ET to delve de...

Announcement

Medpace Holdings (MEDP) Faces Setback as Bookings Miss Expectations, Leading to Share Decline

Published Thu, Oct 10 2024 5:57 PM UTC

In a surprising turn of events, Medpace Holdings, Inc. (NASDAQ: MEDP) has seen its shares tumble following a disappointing bookings report for the third quarter of 2024. Investors were left reeling as Hagens Berman, a well-known legal firm, urged those who felt the impact of the company s financial missteps to come forward and submit their losses. This request signals that t...

Medpace Holdings Inc

2 Medpace Holdings Inc Reports Impressive Financial Growth in Most Recent Fiscal Period

Medpace Holdings Inc, a clinical research organization based in Cincinnati, reported impressive financial results for the most recent fiscal period ending March 31, 2024. The company's profit per share increased by an impressive 40.97% to $3.20 per share, while revenue improved by 17.732% to $511.04 million when compared to the prior year period.
These figures demonstrate significant growth for Medpace Holdings Inc. Earnings also grew by 28.25% from the previous reporting period, rising from $2.50 per share to $3.20 per share. Revenue increased by 2.537% from $498.40 million to $511.04 million.
In terms of net earnings, Medpace Holdings Inc reported $102.591 million for the most recent fiscal period, representing a 40.74% increase from the net earnings of $72.894 million reported in the same period a year ago. This significant growth in earnings reflects the company's strong performance and indicates favorable prospects for investors.

Medpace Holdings Inc

Medpace Holdings Inc Reports Impressive 13.12% Growth in Income for October to December 31, 2023 Financial Period

The stock market is often unpredictable, with ups and downs that can leave investors feeling uncertain. However, there are moments when a company's performance stands out, shining a light on the potential for fruitful investments. Medpace Holdings Inc, a Medical Laboratories company, is one such example, as their recent financial results have surpassed expectations.
In the October to December 31, 2023 financial time-frame, Medpace Holdings Inc's earnings per share (EPS) grew by an impressive 13.12% to $2.50 per share, compared to $2.21 from the previous year. Not only that, but the EPS also grew by 12.39% from $2.22 per share in the preceding quarter. These numbers indicate a consistent upward trend, demonstrating the company's ability to generate greater profits for its shareholders.







Medpace Holdings Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com